Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00142779 · ClinicalTrials.gov registry record · NA
Fluoxetine to Reduce Cocaine Use in Cocaine and Opioid Addicts
A NA study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- NA
- Development phase
- 220
- Enrollment target
NCT00142779 is a NA study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 220 participants.
The verdict
NCT00142779, a NA study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- NA
- Development phase
- 220 participants
- Enrollment target
Study Summary
Cocaine addiction is a serious health problem with no available medical treatment for preventing relapse. Fluoxetine, a medication that is currently used to treat depression and anxiety disorders, may also be effective at diminishing cocaine use in individuals with severe cocaine addiction. This study will evaluate the effectiveness of fluoxetine at reducing cocaine use in individuals addicted to cocaine and opioids who are concurrently receiving methadone treatment.
Interventions
- DRUG Fluoxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2001-04 |
| Est. Completion | 2006-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00142779
The ClinicalTrials.gov registry entry for NCT00142779 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fluoxetine is the first listed.
NCT00142779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00142779 about?
NCT00142779 is a clinical study titled "Fluoxetine to Reduce Cocaine Use in Cocaine and Opioid Addicts". Cocaine addiction is a serious health problem with no available medical treatment for preventing relapse. Fluoxetine, a medication that is currently used to treat depression and anxiety disorders, may also be effective at diminishing cocaine use in individuals with severe cocaine addiction. This stu...
What is the current status of trial NCT00142779?
This trial is currently completed. It is a NA study. The enrollment target is 220 participants. The study started on 2001-04. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00142779?
The interventions under investigation include: Fluoxetine (DRUG).
Who is sponsoring clinical trial NCT00142779?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.